NYSE:AEON
AEON Biopharma, Inc.
A pre-revenue biopharma firm with strong R&D spending but negative shareholder equity and no reported annual revenue.
Key Metrics
Investment Thesis
Bull Case
An investor might buy based on the potential for a blockbuster drug discovery that could reverse the company's negative equity position upon commercialization. The massive paid-in capital of $403M suggests strong backing from investors or strategic partners willing to fund high-risk R&D projects. If the pipeline succeeds, the current lack of revenue and zero cost structure positions the company for explosive growth margins once products launch.
Bear Case
The stock should be avoided due to the critical risk of insolvency given the -$28.6M shareholder equity and deep retained earnings deficit of -$431.6M. With no commercial revenue generated and cash flow from operations draining liquidity at a rate of $20.3M, the company lacks a sustainable business model outside of continuous financing. The financial data indicates the company is essentially an asset-heavy liability structure with no proven path to profitability in the current fiscal period.
About AEON Biopharma, Inc.
AEON Biopharma, Inc. is a biotechnology company focused on developing innovative therapies, primarily operating within the US markets. Despite reporting significant net income in recent years, the company's financial statements show minimal revenue and substantial operating losses typical of early-stage R&D. Key data points include $14.2M spent on research and development and a massive deficit in retained earnings.
Analysis
Management Discussion
Management has successfully generated reported net profits of $42.0M over the last two years, yet this is not translating into positive operating cash flows which hit -$20.3M in the latest period. The company continues to burn cash for R&D initiatives totaling $14.2M while maintaining a negative working capital position with current liabilities exceeding current assets. Investors must scrutinize the non-cash adjustments of -$65.2M as these figures may distort the true economic performance of the business.
Industry Overview
The biopharma industry is characterized by high upfront capital requirements for research and development before any commercial revenue is recognized. Companies often operate at a loss for years while building intellectual property portfolios and conducting clinical trials. Market leaders typically transition from negative cash flow operations to positive cash generation once products receive FDA approval and enter the market.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | — | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | — | $0 |
| Operating Expenses | $3.3M | — | $-73.0M |
| Operating Income | $-3.3M | — | $73.0M |
| R&D | — | — | $14.2M |
| G&A | — | — | $13.6M |
| Stock-Based Comp | — | — | $6.2M |
| D&A | — | — | $97.0K |
| Other OpEx | — | — | $-100.8M |
| Non-Operating Income | $14.2M | $0 | $-31.0M |
| Interest Income | $3.7M | — | — |
| Pre-Tax Income | $10.9M | — | $42.0M |
| Income Tax | $883.3K | — | $0 |
| Continuing Ops | $10.0M | — | $42.0M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $10.0M | — | $42.0M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $10.0M | — | $42.0M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $109.2K | $6.2M | $1.6M |
| Cash & Equivalents | — | $5.2M | $13.0K |
| Prepaid Expenses | — | $1.1M | $1.6M |
| Other Current Assets | — | $0 | $0 |
| Long-Term Assets | $279.4M | $623.0K | $1.6M |
| PP&E (Net) | — | $332.0K | $235.0K |
| Operating Leases | — | $262.0K | $1.3M |
| Other LT Assets | — | $29.0K | $29.0K |
| Total Assets | $279.5M | $6.8M | $3.1M |
| Current Liabilities | $3.9M | $13.0M | $14.1M |
| Accounts Payable | — | $3.4M | $5.9M |
| Current Leases | — | $278.0K | $121.0K |
| Taxes Payable | $294.4K | — | — |
| Other Current Liab | $3.6M | $9.4M | $8.1M |
| Long-Term Liabilities | $6.6M | $146.8M | $17.6M |
| LT Operating Leases | — | — | $1.1M |
| Other LT Liab | — | — | $16.4M |
| Total Liabilities | $10.4M | $159.9M | $31.7M |
| Shareholders' Equity | $269.1M | $-153.0M | $-28.6M |
| Paid-In Capital | $32.0K | $381.3M | $403.0M |
| Retained Earnings | $-9.5M | $-473.6M | $-431.6M |
| Total L&E | $279.5M | $6.8M | $3.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $10.0M | — | $42.0M |
| Non-Cash Adjustments | $-12.6M | — | $-65.2M |
| Working Capital Changes | $1.7M | — | $2.9M |
| Cash from Operations | $-981.4K | — | $-20.3M |
| Cash from Investing | $401.9K | — | $0 |
| Cash from Financing | $150.0K | — | $15.1M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-429.5K | $-4.6M | $-5.1M |
| Beginning Cash | $497.4K | $9.7M | $5.2M |
| Ending Cash | $67.9K | $5.2M | $13.0K |
Frequently Asked Questions
How does AEON Biopharma, Inc. make money?
The company's activities are concentrated in drug discovery and clinical development rather than commercial sales, evidenced by zero cost of revenue and gross profit. Operations are heavily weighted towards research and development expenses alongside high general and administrative costs. Financing activities suggest reliance on capital markets for liquidity given the lack of operational cash flow.
What are the main risks for AEON?
The company reports $0 revenue and $0 cost of revenue, indicating it has not yet commercialized a product, creating high business risk. Shareholders' equity is deeply negative at -$28.6M with a retained earnings deficit of -$431.6M, signaling potential insolvency or aggressive accounting. Cash flow from operations is significantly negative at -$20.3M while ending cash remains low at $13M, creating liquidity pressure. The mismatch between positive net income and negative operating cash flow suggests non-cash adjustments totaling -$65.2M may be masking underlying operational weakness.
What is AEON's competitive advantage?
The company has secured significant paid-in capital of $403M, providing a robust runway for expensive clinical trials. Strong operating profit margins relative to revenue (due to lack of cost of goods) indicate efficient management of current limited operations. The ability to generate net income despite zero revenue suggests successful grant funding or specific accounting treatments for R&D assets.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.